At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 168 enrolled
Drug / intervention
Pandemrix (Influenza vaccine GSK2340272A) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix™ 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older
In Brief
A Phase 2 clinical trial evaluating Pandemrix (Influenza vaccine GSK2340272A), Fluarix™, and 1 other intervention for Influenza. Completed, enrolled 168 participants across 2 sites.
Detailed Summary
The purpose of the present study is to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with vaccine GSK2340272A when co-administered with GSK Biologicals' Fluarix™ vaccine either at the time of first or second vaccination in elderly subjects aged 61 years and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedAug 31, 2009
Enrollment StartSep 12, 2009
Primary CompletionSep 23, 2010
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 16.8 years ago
Interventions
Pandemrix (Influenza vaccine GSK2340272A)biological
Intramuscular injection, 2 doses
Fluarix™biological
Intramuscular injection, 1 dose
Placebobiological
Intramuscular injection, 1 dose